Answer
The licence includes men receiving adjuvant treatment for eligible early breast cancer with an aromatase inhibitor and an LHRH agonist. The selected product’s advanced-disease indication is worded for women.
Sources for this answer
- Kisqali film coated tabletsemc · SmPC Current selected SmPC · Version 25